AI in Biotech and Healthcare: Translational Signals Outpace Clinical Deployment

AI drug discovery combines candidate-level clinical signals, multimodal infrastructure, laboratory automation, and major-pharma adoption: rentosertib's small Phase IIa study remains intriguing but insufficient for aging or efficacy claims, while AlphaGenome Atlas and Tempus add research infrastructure. Novo Nordisk's Claude Science trial and accelerated cell-free/SPR screening show workflow adoption, while ML-guided lipoprotein(a) testing across five health systems moves toward prospective evaluation; clinical utility and patient outcomes remain unproven.